A case of Rowell syndrome with excellent improvement following anifrolumab

Chelsea Shope; Laura Andrews; Melissa Cunningham; Jessica Connett

doi:10.1016/j.jdcr.2022.11.008

A case of Rowell syndrome with excellent improvement following anifrolumab

JAAD Case Rep. 2022 Nov 13:31:27-30. doi: 10.1016/j.jdcr.2022.11.008. eCollection 2023 Jan.

Authors

Chelsea Shope¹, Laura Andrews¹, Melissa Cunningham², Jessica Connett³

Affiliations

¹ College of Medicine, Medical University of South Carolina, Charleston, South Carolina.
² Department of Rheumatology, Medical University of South Carolina, Charleston, South Carolina.
³ Department of Dermatology & Dermatologic Surgery, Medical University of South Carolina, Charleston, South Carolina.

No abstract available

Keywords: BAFF, B cell-activating factor; CLE, cutaneous lupus erythematosus; DIF, direct immunofluorescence; DLE, discoid lupus erythematosus; EM, erythema multiforme; HAART, highly active antiretroviral therapy; HCQ, hydroxychloroquine; HIV, human immunodeficiency virus; IFNAR1, interferon- α receptor 1; IL, intralesional; IVIg, intravenous immunoglobulin; LE, lupus erythematosus; MMF, mycophenolate mofetil; PIPA, post inflammatory pigment alteration; RS, Rowell syndrome; Rowell syndrome; SCLE, subacute cutaneous lupus erythematosus; SLE, systemic lupus erythematous; anifrolumab; cutaneous lupus erythematous; immunotherapy.

Publication types

Case Reports